Cargando…
Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
INTRODUCTION: Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028035/ https://www.ncbi.nlm.nih.gov/pubmed/36281472 http://dx.doi.org/10.1002/cam4.5341 |
_version_ | 1784909848949817344 |
---|---|
author | Zhang, Jiahui Kong, Weili Hu, Pingzhao Jonker, Derek Moore, Malcolm Ringash, Jolie Shapiro, Jeremy Zalcberg, John Simes, John Tu, Dongsheng O'Callaghan, Chris J. Liu, Geoffrey Xu, Wei |
author_facet | Zhang, Jiahui Kong, Weili Hu, Pingzhao Jonker, Derek Moore, Malcolm Ringash, Jolie Shapiro, Jeremy Zalcberg, John Simes, John Tu, Dongsheng O'Callaghan, Chris J. Liu, Geoffrey Xu, Wei |
author_sort | Zhang, Jiahui |
collection | PubMed |
description | INTRODUCTION: Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations (“patient clusters”) in the CO.20 clinical trial longitudinal QoL data. Classes were then evaluated for differences in clinico‐epidemiologic characteristics and overall survival (OS). METHODS AND MATERIALS: In CO.20, 750 chemotherapy‐refractory metastatic colorectal cancer (CRC) patients were randomized to receive Brivanib+Cetuximab (n = 376, experimental arm) versus Cetuximab+Placebo (n = 374, standard arm) for 16 weeks. EORTC‐QLQ‐C30 QoL summary scores were calculated for each patient at seven time points, and GMM was applied to identify patient clusters (termed “classes”). Log‐rank/Kaplan–Meier and multivariable Cox regression analyses were conducted to analyze the survival performance between classes. Cox analyses were used to explore the relationship between baseline QoL, individual slope, and the quadratic terms from the GMM output with OS. RESULTS: In univariable analysis, the linear mixed effect model (LMM) identified sex and ECOG Performance Status as strongly associated with the longitudinal QoL score (p < 0.01). The patients within each treatment arm were clustered into three distinct QoL‐based classes by GMM, respectively. The three classes identified in the experimental (log‐rank p‐value = 0.00058) and in the control arms (p < 0.0001) each showed significantly different survival performance. The GMM's baseline, slope, and quadratic terms were each significantly associated with OS (p < 0.001). CONCLUSION: GMM can be used to analyze longitudinal QoL data in cancer studies, by identifying unobserved subpopulations (patient clusters). As demonstrated by CO.20 data, these classes can have important implications, including clinical prognostication. |
format | Online Article Text |
id | pubmed-10028035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100280352023-03-22 Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial Zhang, Jiahui Kong, Weili Hu, Pingzhao Jonker, Derek Moore, Malcolm Ringash, Jolie Shapiro, Jeremy Zalcberg, John Simes, John Tu, Dongsheng O'Callaghan, Chris J. Liu, Geoffrey Xu, Wei Cancer Med RESEARCH ARTICLES INTRODUCTION: Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations (“patient clusters”) in the CO.20 clinical trial longitudinal QoL data. Classes were then evaluated for differences in clinico‐epidemiologic characteristics and overall survival (OS). METHODS AND MATERIALS: In CO.20, 750 chemotherapy‐refractory metastatic colorectal cancer (CRC) patients were randomized to receive Brivanib+Cetuximab (n = 376, experimental arm) versus Cetuximab+Placebo (n = 374, standard arm) for 16 weeks. EORTC‐QLQ‐C30 QoL summary scores were calculated for each patient at seven time points, and GMM was applied to identify patient clusters (termed “classes”). Log‐rank/Kaplan–Meier and multivariable Cox regression analyses were conducted to analyze the survival performance between classes. Cox analyses were used to explore the relationship between baseline QoL, individual slope, and the quadratic terms from the GMM output with OS. RESULTS: In univariable analysis, the linear mixed effect model (LMM) identified sex and ECOG Performance Status as strongly associated with the longitudinal QoL score (p < 0.01). The patients within each treatment arm were clustered into three distinct QoL‐based classes by GMM, respectively. The three classes identified in the experimental (log‐rank p‐value = 0.00058) and in the control arms (p < 0.0001) each showed significantly different survival performance. The GMM's baseline, slope, and quadratic terms were each significantly associated with OS (p < 0.001). CONCLUSION: GMM can be used to analyze longitudinal QoL data in cancer studies, by identifying unobserved subpopulations (patient clusters). As demonstrated by CO.20 data, these classes can have important implications, including clinical prognostication. John Wiley and Sons Inc. 2022-10-24 /pmc/articles/PMC10028035/ /pubmed/36281472 http://dx.doi.org/10.1002/cam4.5341 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Zhang, Jiahui Kong, Weili Hu, Pingzhao Jonker, Derek Moore, Malcolm Ringash, Jolie Shapiro, Jeremy Zalcberg, John Simes, John Tu, Dongsheng O'Callaghan, Chris J. Liu, Geoffrey Xu, Wei Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial |
title | Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial |
title_full | Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial |
title_fullStr | Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial |
title_full_unstemmed | Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial |
title_short | Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial |
title_sort | clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: implementation on cctg/agitg co.20 trial |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028035/ https://www.ncbi.nlm.nih.gov/pubmed/36281472 http://dx.doi.org/10.1002/cam4.5341 |
work_keys_str_mv | AT zhangjiahui clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT kongweili clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT hupingzhao clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT jonkerderek clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT mooremalcolm clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT ringashjolie clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT shapirojeremy clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT zalcbergjohn clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT simesjohn clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT tudongsheng clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT ocallaghanchrisj clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT liugeoffrey clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial AT xuwei clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial |